Fireside Chat: Clinical data thresholds, funding strategies and risk management

Translating advanced therapies from research to market requires careful alignment of clinical evidence, capital allocation, and risk tolerance. Investors seek robust yet efficient data packages, while developers must balance resource constraints with regulatory and commercial expectations. This fireside chat explores practical approaches for managing these interdependencies. 

Key takeaways: 

• Define the clinical data thresholds investors and regulators expect at early and late stages. 

• Explore funding strategies that align with development milestones and risk profiles. 

• Assess approaches to de-risk therapy pipelines through adaptive trial design and biomarker strategy. 

• Discuss how capital efficiency influences decision making for biotech growth. 

• Identify common pitfalls in balancing data generation, funding, and risk management.